Pharmaceutical group ยท France
Ipsen
A group of 23 companies with 150 medicines in 10 countries.
Loading your pageโฆ
Loading your pageโฆ
Pharmaceutical group ยท France
A group of 23 companies with 150 medicines in 10 countries.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
23 companies in 11 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1โ25 of 150
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALLUZIENCESoluzione iniettabile | Botulinum toxin | Italy | Authorised | |
| Alluzience 200 Speywood-eenheden/ml oplossing voor injectieOplossing voor injectie | Botulinum toxin | Netherlands | Authorised | 2021 |
| Alluzience 200 Speywood jedinica/ml otopina za injekcijuotopina za injekciju | Botulinum toxin | Croatia | Marketed | 2026 |
| ALLUZIENCE 200 UNIDADES SPEYWOOD/ML SOLUCION INYECTABLE200 U/ml ยท Soluciรณn inyectable | Toxina botulinica tipo a | Spain | Marketed | 2021 |
| AZZALUREPolvere per soluzione iniettabile | Botulinum toxin | Italy | Authorised | |
| Azzalure, 125 Speywood-eenheden, poeder voor oplossing voor injectiePoeder voor oplossing voor injectie | Botulinum toxin | Netherlands | Authorised | 2010 |
| Azzalure 125 Speywood jedinica, praลกak za otopinu za injekcijupraลกak za otopinu za injekciju | Botulinum toxin | Croatia | Marketed | 2023 |
| AZZALURE 125 UNIDADES SPEYWOOD POLVO PARA SOLUCION INYECTABLE125 dl50 ยท Polvo para soluciรณn inyectable | Toxina botulinica tipo a | Spain | Marketed | 2009 |
| BYLVAYCapsula rigida | Odevixibat | Italy | Authorised | |
| Bylvay | Odevixibat | EU (EMA) | Authorised | 2021 |
| BYLVAY0.2mg | 0.6mg ยท Capsule, pellets | Odevixibat | United States | Marketed | 2021 |
| BYLVAY0.4mg | 1.2mg ยท Capsule | Odevixibat | United States | Marketed | 2021 |
| Bylvay 1200 micorgram harde capsulesCapsule, hard | Odevixibat | Netherlands | Authorised | 2021 |
| BYLVAY 1200 MICROGRAMOS CAPSULAS DURAS1,244 mg ยท Cรกpsula dura | Odevixibat | Spain | Marketed | 2021 |
| Bylvay 200 microgram harde capsulesCapsule, hard | Odevixibat | Netherlands | Authorised | 2021 |
| BYLVAY 200 MICROGRAMOS CAPSULAS DURAS0,207 mg ยท Cรกpsula dura | Odevixibat | Spain | Marketed | 2021 |
| Bylvay 400 microgram harde capsulesCapsule, hard | Odevixibat | Netherlands | Authorised | 2021 |
| BYLVAY 400 MICROGRAMOS CAPSULAS DURAS0,414 mg ยท Cรกpsula dura | Odevixibat | Spain | Marketed | 2021 |
| Bylvay 600 microgram harde capsulesCapsule, hard | Odevixibat | Netherlands | Authorised | 2021 |
| BYLVAY 600 MICROGRAMOS CAPSULAS DURAS0,622 mg ยท Cรกpsula dura | Odevixibat | Spain | Marketed | 2021 |
| Cabometyx | Cabozantinib | EU (EMA) | Authorised | 2016 |
| CABOMETYX40 mg ยท Tablet | Cabozantinib | Canada | Marketed | 2018 |
| CABOMETYXCompressa rivestita con film | Cabozantinib | Italy | Authorised | |
| CABOMETYX60 mg ยท Tablet | Cabozantinib | Canada | Marketed | 2018 |
| CABOMETYX20 mg ยท Tablet | Cabozantinib | Canada | Marketed | 2018 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 33 | 31 | 2 | CompaniesAll medicines |
| Netherlands | 29 | 29 | 0 | CompaniesAll medicines |
| Romania | 20 | 0 | 20 | CompaniesAll medicines |
| Canada | 19 | 17 | 2 | CompaniesAll medicines |
| Italy | 12 | 12 | 0 | CompaniesAll medicines |
| Singapore | 11 | 11 | 0 |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
| European Union (EMA) | 8 | 7 | 1 | CompaniesAll medicines |
|---|
| United States | 8 | 8 | 0 | CompaniesAll medicines |
|---|
| Saudi Arabia | 7 | 7 | 0 | CompaniesAll medicines |
|---|
| Croatia | 3 | 3 | 0 | CompaniesAll medicines |
|---|
Also in the registers of Brazil, France, Serbia, United Kingdom
Licence: Open Government Licence Canada
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sฤnฤtฤศii, Catalogul public naลฃional al preลฃurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.
Ranked by their number of medicines.